LYN-013

**LYN-013** is Lyndra's investigational once-weekly oral, gastric-resident extended-release capsule for opioid use disorder. The product was developed using Lyndra's long-acting oral delivery technology to maintain systemic exposure to buprenorphine over approximately one week after a single capsule. In reported preclinical work, LYN-013 co-formulated buprenorphine hydrochloride and naloxone hydrochloride at an 11:1 ratio; buprenorphine provides partial mu-opioid receptor agonism for medication treatment of opioid use disorder, while naloxone is included as an abuse-deterrence component. In rhesus monkeys, the formulation produced prolonged buprenorphine exposure and reduced fentanyl self-administration. ([businesswire.com](https://www.businesswire.com/news/home/20210625005069/en/Lyndra-Therapeutics-Presents-Preclinical-Data-on-Once-Weekly-Oral-Buprenorphine-Treatment-LYN-013-in-Development-for-Opioid-Use-Disorder))